PubMed · 1995 · 27 citations · 12 references
MedicineSurgeryHepatologyTransplant SurgeryLiver DiseaseLiver TransplantationTransplant PharmacologyTransplant RejectionAcute Adverse EventsLiver Transplant RejectionPharmacokinetics In Liver TransplantationSerious Adverse Events
FK 506 (Tacrolimus, Prograf™) has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1989,1 and 1 year later at the Thirteenth International Congress of Transplantation Society, San Francisco, CA, 1990, extensive reports were given from our center describing the potential value of this drug in clinical transplantation.2–5 We have so far treated 1497 primary liver transplant recipients with FK 506 and an additional 512 patients who were converted to FK 506 from cyclosporine (CyA). This report will focus on the first 1000 consecutive primary OLTs in the series. The parameters examined were patient and graft survival, causes of death and retransplant, effect of age, United Network for Organ Sharing (UNOS) status, level of maintenance immunosuppression, and adverse events.
12
FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION
ThomasE. Starzl, John J. Fung, Raman Venkataramman et al. · The Lancet · 1989 · 1.1K citations
Medicine, Pharmacokinetics, Surgery +12
Liver, Kidney, and Thoracic Organ Transplantation Under FK 506
Satoru Todo, John J. Fung, Thomas E. Starzl et al. · Annals of Surgery · 1990 · 255 citations
Medicine, Pharmacotherapy, Surgery +15
Kidney Transplantation Under FK 506
T. E. Starzl · JAMA · 1990 · 234 citations
Medicine, Immunology, Pharmacology +17
THE ADVERSE IMPACT ON LIVER TRANSPLANTATION OF USING POSITIVE CYTOTOXIC CROSSMATCH DONORS 1, 2
S Takaya, Oscar Bronsther, Yuichi Iwaki et al. · Transplantation · 1992 · 126 citations
Medicine, Immunology, Surgery +12